SciSparc Ltd. SPRC

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$1.3M$2.9M$1.3M——————
SG&A —————$1.9M$2.5M$4.4M——
Operating income —-$7.3M-$6.8M-$8.3M-$5.8M-$3.3M-$4.1M-$7.2M-$5.8M-$2.0M
Net income —-$7.5M-$5.9M-$2.6M-$5.8M-$3.5M-$4.7M-$8.9M-$6.2M-$2.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets —$10.3M$11.2M$10.6M$9.9M$2.6M$1.2M$4.6M$9.6M$1.2M
Total equity —$8.9M$9.6M$6.4M$8.1M$1.4M$14.0K$77.0K$8.4M$573.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-091427.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10M -5M 0 5M Net income, FY2016: -2M Net income, FY2017: -6.2M Net income, FY2018: -8.9M Net income, FY2019: -4.7M Net income, FY2020: -3.5M Net income, FY2021: -5.8M Revenue, FY2022: 1.3M Net income, FY2022: -2.6M Revenue, FY2023: 2.9M Net income, FY2023: -5.9M Revenue, FY2024: 1.3M Net income, FY2024: -7.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — $1.3M $2.9M $1.3M —
Gross profit — — — — — — — — — —
Net income -$2.0M -$6.2M -$8.9M -$4.7M -$3.5M -$5.8M -$2.6M -$5.9M -$7.5M —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%